ReviewDrug design, development and therapy2026
Research Advances on the Molecular Structural Basis and Mechanisms of Quercetin and Its Derivatives in Improving Insulin Resistance.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin resistance is a core pathological link in metabolic diseases such as type 2 diabetes, and its prevention and treatment are current research hotspots. Quercetin, a natural flavonoid, has significant potential to improve insulin resistance through its anti-inflammatory, antioxidant, and metabolic regulatory activities. This review systematically examines literature published between 2020 and 2025 from the PubMed, Web of Science, and Scopus databases, focusing on original mechanistic studies in cellular and animal models of insulin resistance. Our synthesis reveals two mechanistic clusters: quercetin directly activates insulin signaling via the insulin receptor substrate 1/Phosphatidylinositol 3-kinase /Protein Kinase B pathway, enhances muscle glucose uptake through AMP-activated protein kinase-dependent glucose transporter 4 translocation. Indirect mechanisms include gut microbiome modulation with increased short-chain fatty acid production, suppresses hepatic inflammation and targeting of transcription factors. Critically, a clear efficacy hierarchy among derivatives was identified: glycosides show superior bioavailability compared to the aglycone, while methylated derivatives exhibit enhanced stability but divergent effects on peroxisome proliferator-activated receptor γ signaling. Major unresolved challenges include the low oral bioavailability of quercetin aglycone, the lack of systematic structure-activity relationship models, and the absence of rigorous human trials. The review concludes that chemical derivatization and advanced delivery systems offer promising strategies, but clinical translation requires an integrated framework combining systematic structure-activity profiling, mechanistic target selection, and validated human studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.